Business
Cumberland Pharmaceuticals Announces Initiative To Expand Availability Of VIBATIV® To Treat Hospital-Acquired & Ventilator-Associated Pneumonia Resulting From Coronavirus Infections
- Response to COVID-19 Crisis Includes Special Supply Arrangements for U.S. Hospitals - Initiative Designed to Help Address Potential Antibiotic Shortages -
About this update from Cumberland Pharmaceuticals Inc.
[{"type":"text","content":"- Response to COVID-19 Crisis Includes Special Supply Arrangements for U.S. Hospitals\n - Initiative Designed to Help Address Potential Antibiotic Shortages\n - Sponsoring an Expert Infectious Disease Panel Discussion of the Management of Complicated Respiratory Infections Resulting from COVID-19\n\n\nNASHVILLE, Tenn., March 23, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, today announced a national initiative to support the treatment of patients with hospital-acquired and ventilator-associated pneumonia associated with the outbreak of the COVID-19 coronavirus. \n\n \n \n \n \n \n \n\n \nPneumonia caused by secondary bacterial infections – such as a Gram-positive bacterial infection – is common among patients with viral respiratory infections. Furthermore, pneumonia was the leading cause of death in patients suffering from the 1918 Spanish Flu pandemic, which was prior to the use of antibiotics, according to a manuscript co-authored by Dr. Anthony S. Fauci, the current director of the U.S. National Institute of Allergy and Infectious Diseases.1\nCumberland's initiative includes the availability of special financial arrangements for hospitals and clinics to help ensure supply during this unprecedented healthcare crisis. In addition, Cumberland is sponsoring a national program with infectious disease experts to provide information on the management of complicated respiratory infections resulting from the novel coronavirus.\nCumberland manufactures the potent antibiotic VIBATIV® (telavancin) injection, designed to treat serious infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA).\n\"We have been closely monitoring the evolving COVID-19 situation and its impact on our country, including our economy, financial markets and health care system,\" said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. \"Based on recommendations from the Centers for Disease Control (CDC), we are taking appropriate action to secure our supply chain, support hospitals and clinics, and assure the supply of our medications.\"\nThe special financial arrangements being offered by Cumberland include extended payment terms for all dir...